Heart failure & cardiomyopathiesMeta-analysis
Cardiovascular Burden of the V142I Transthyretin Variant
- Pooled analysis of 4 observational cohort studies
- 4 large observational studies across the US
Authors' conclusion
Among self-reported Black individuals, male and female V142I carriers faced similar and substantial risk for HF hospitalization, predominantly with reduced ejection fraction, and death, with steep age-dependent penetrance.
Study context
- Population
- Self-reported Black participants initially free from heart failure (HF), US; mean age 62 years, 76.7% women
- Participants
- 23,338 participants · 4 cohorts
- Comparison
- V142I the transthyretin (TTR) carriers vs non-carriers
- V142I carriersn = 754
- Outcome
- HF hospitalization (including HF with reduced and preserved EF) and all-cause mortality; 10-year HRs for each age 50–90 years
- Follow-up
- 10 years
Pooled result
As reported in the abstract
HF hospitalization and all-cause mortality
- 10-year carrier risk of HF hospitalization increased by age 63 years, predominantly driven by HF with reduced EF
- 10-year all-cause mortality risk increased by age 72 years
- mean (SD) follow-up 15.5 (8.2) years
Further pooled results
Estimated reduction in longevity with the variant, by age
- Reduction in longevity at age 50: 1.9 years
- 1.9 (95% CI, 0.6-3.1)
- Reduction in longevity at age 81: 2.8 years
- 2.8 (95% CI, 2.0-3.6)
- Only age (not sex or other select variables) modified risk with the variant
Projected years of life lost, US Black carriers aged 50–95 years (2022 US population)
- 435 851 estimated carriers projected to cumulatively lose 957 505 years of life
- 957 505 (95% CI, 534 475-1 380 535)
Original publication
Cardiovascular Burden of the V142I Transthyretin Variant. JAMA. Published 4 June 2024. doi:10.1001/jama.2024.4467
Summarised from the published abstract; every number is checked against it